Literature DB >> 8636429

Modulation of very low density lipoprotein production and clearance contributes to age- and gender- dependent hyperlipoproteinemia in apolipoprotein E3-Leiden transgenic mice.

B J van Vlijmen1, H B van 't Hof, M J Mol, H van der Boom, A van der Zee, R R Frants, M H Hofker, L M Havekes.   

Abstract

Apolipoprotein E3-Leiden (APOE*3-Leiden) transgenic mice have been studied to identify factors modulating chylomicron and VLDL remnant lipoprotein metabolism. Transient elevated levels of VLDL/LDL-sized lipoproteins occurred in these mice with maximal levels during the period of rapid growth (optimum at 45 d of age). After about 100 d of age, serum cholesterol and triglyceride levels stabilized to slightly elevated levels as compared to control mice. The expression of the APOE*3-Leiden transgene was not age-dependent. In young mice the in vivo hepatic production of VLDL-triglycerides was 50% increased as compared to older mice. This is sustained by in vivo VLDL-apo B turnover studies showing increased (75%) VLDL-apo B secretion rates in young mice, whereas the VLDL-apo B clearance rate appeared not to be age dependent. On a high fat/cholesterol diet, females displayed significantly higher cholesterol levels than males (10 versus 7.0 mmol/liter, respectively). Serum levels of VLDL/LDL sized lipoproteins increased upon administration of estrogens, whereas administration of testosterone gave the opposite result. As compared to male mice, in female mice the hepatic VLDL-triglyceride production rate was significantly elevated. Injection of estrogen in males also resulted in increased VLDL-triglyceride production, although not statistically significant. In vivo VLDL-apo B turnover experiments showed that the VLDL secretion rate tended to be higher in females. Although, the fractional catabolic rate of VLDL-apo B is not different between males and females, administration of estrogens in males resulted in a decreased clearance rate of VLDL, whereas administration of testosterone in females resulted in an increased clearance rate of VLDL. The latter presumably due to an inhibiting effect of testosterone on the expression of the APOE*3-Leiden transgene. We conclude that hyperlipidemia in APOE*3-Leiden transgenic mice is strongly affected by age via its effect on hepatic VLDL production rate, whereas gender influences hyperlipidemia by modulating both hepatic VLDL production and clearance rate.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8636429      PMCID: PMC507170          DOI: 10.1172/JCI118532

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  36 in total

1.  Increased binding of low density lipoprotein to liver membranes from rats treated with 17 alpha-ethinyl estradiol.

Authors:  P T Kovanen; M S Brown; J L Goldstein
Journal:  J Biol Chem       Date:  1979-11-25       Impact factor: 5.157

2.  Effects of ethynyl estradiol on serum lipoprotein lipids in male and female rats.

Authors:  I Weinstein; F C Turner; C Soler-Argilaga; M Heimberg
Journal:  Biochim Biophys Acta       Date:  1978-09-28

3.  Carbohydrate diet-induced changes in very low density lipoprotein composition and structure.

Authors:  J L Witztum; G Schonfeld
Journal:  Diabetes       Date:  1978-12       Impact factor: 9.461

4.  The metabolism of very low density lipoprotein proteins. I. Preliminary in vitro and in vivo observations.

Authors:  D W Bilheimer; S Eisenberg; R I Levy
Journal:  Biochim Biophys Acta       Date:  1972-02-21

5.  Rapid hepatic clearance of the canine lipoproteins containing only the E apoprotein by a high affinity receptor. Identity with the chylomicron remnant transport process.

Authors:  B C Sherrill; T L Innerarity; R W Mahley
Journal:  J Biol Chem       Date:  1980-03-10       Impact factor: 5.157

6.  Hepatic catabolism of rat and human lipoproteins in rats treated with 17 alpha-ethinyl estradiol.

Authors:  Y S Chao; E E Windler; G C Chen; R J Havel
Journal:  J Biol Chem       Date:  1979-11-25       Impact factor: 5.157

7.  Delayed clearance of very low density and intermediate density lipoproteins with enhanced conversion to low density lipoprotein in WHHL rabbits.

Authors:  T Kita; M S Brown; D W Bilheimer; J L Goldstein
Journal:  Proc Natl Acad Sci U S A       Date:  1982-09       Impact factor: 11.205

8.  The estradiol-stimulated lipoprotein receptor of rat liver. A binding site that membrane mediates the uptake of rat lipoproteins containing apoproteins B and E.

Authors:  E E Windler; P T Kovanen; Y S Chao; M S Brown; R J Havel; J L Goldstein
Journal:  J Biol Chem       Date:  1980-11-10       Impact factor: 5.157

9.  Diet-induced hypercholesterolemia and atherosclerosis in heterozygous apolipoprotein E-deficient mice.

Authors:  J H van Ree; W J van den Broek; V E Dahlmans; P H Groot; M Vidgeon-Hart; R R Frants; B Wieringa; L M Havekes; M H Hofker
Journal:  Atherosclerosis       Date:  1994-11       Impact factor: 5.162

10.  Isoprotein specificity in the hepatic uptake of apolipoprotein E and the pathogenesis of familial dysbetalipoproteinemia.

Authors:  R J Havel; Y Chao; E E Windler; L Kotite; L S Guo
Journal:  Proc Natl Acad Sci U S A       Date:  1980-07       Impact factor: 11.205

View more
  15 in total

1.  Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease.

Authors:  Frederick E Dewey; Viktoria Gusarova; Richard L Dunbar; Colm O'Dushlaine; Claudia Schurmann; Omri Gottesman; Shane McCarthy; Cristopher V Van Hout; Shannon Bruse; Hayes M Dansky; Joseph B Leader; Michael F Murray; Marylyn D Ritchie; H Lester Kirchner; Lukas Habegger; Alex Lopez; John Penn; An Zhao; Weiping Shao; Neil Stahl; Andrew J Murphy; Sara Hamon; Aurelie Bouzelmat; Rick Zhang; Brad Shumel; Robert Pordy; Daniel Gipe; Gary A Herman; Wayne H H Sheu; I-Te Lee; Kae-Woei Liang; Xiuqing Guo; Jerome I Rotter; Yii-Der I Chen; William E Kraus; Svati H Shah; Scott Damrauer; Aeron Small; Daniel J Rader; Anders Berg Wulff; Børge G Nordestgaard; Anne Tybjærg-Hansen; Anita M van den Hoek; Hans M G Princen; David H Ledbetter; David J Carey; John D Overton; Jeffrey G Reid; William J Sasiela; Poulabi Banerjee; Alan R Shuldiner; Ingrid B Borecki; Tanya M Teslovich; George D Yancopoulos; Scott J Mellis; Jesper Gromada; Aris Baras
Journal:  N Engl J Med       Date:  2017-05-24       Impact factor: 91.245

2.  In the absence of the low density lipoprotein receptor, human apolipoprotein C1 overexpression in transgenic mice inhibits the hepatic uptake of very low density lipoproteins via a receptor-associated protein-sensitive pathway.

Authors:  M C Jong; V E Dahlmans; P J van Gorp; K W van Dijk; M L Breuer; M H Hofker; L M Havekes
Journal:  J Clin Invest       Date:  1996-11-15       Impact factor: 14.808

3.  Maternal undernutrition programmes atherosclerosis in the ApoE*3-Leiden mouse.

Authors:  Zoe Yates; Elizabeth J Tarling; Simon C Langley-Evans; Andrew M Salter
Journal:  Br J Nutr       Date:  2008-09-10       Impact factor: 3.718

4.  ApoE2-associated hypertriglyceridemia is ameliorated by increased levels of apoA-V but unaffected by apoC-III deficiency.

Authors:  Gery Gerritsen; Caroline C van der Hoogt; Frank G Schaap; Peter J Voshol; Kyriakos E Kypreos; Nobuyo Maeda; Albert K Groen; Louis M Havekes; Patrick C N Rensen; Ko Willems van Dijk
Journal:  J Lipid Res       Date:  2008-02-10       Impact factor: 5.922

5.  The androgen receptor confers protection against diet-induced atherosclerosis, obesity, and dyslipidemia in female mice.

Authors:  Johan B Fagman; Anna S Wilhelmson; Benedetta M Motta; Carlo Pirazzi; Camilla Alexanderson; Karel De Gendt; Guido Verhoeven; Agneta Holmäng; Fredrik Anesten; John-Olov Jansson; Malin Levin; Jan Borén; Claes Ohlsson; Alexandra Krettek; Stefano Romeo; Åsa Tivesten
Journal:  FASEB J       Date:  2014-12-30       Impact factor: 5.191

6.  Male apoE*3-Leiden.CETP mice on high-fat high-cholesterol diet exhibit a biphasic dyslipidemic response, mimicking the changes in plasma lipids observed through life in men.

Authors:  Yared Paalvast; Albert Gerding; Yanan Wang; Vincent W Bloks; Theo H van Dijk; Rick Havinga; Ko Willems van Dijk; Patrick C N Rensen; Barbara M Bakker; Jan Albert Kuivenhoven; Albert K Groen
Journal:  Physiol Rep       Date:  2017-10-16

7.  The BCR-ABL1 Inhibitors Imatinib and Ponatinib Decrease Plasma Cholesterol and Atherosclerosis, and Nilotinib and Ponatinib Activate Coagulation in a Translational Mouse Model.

Authors:  Marianne G Pouwer; Elsbet J Pieterman; Lars Verschuren; Martien P M Caspers; Cornelis Kluft; Ricardo A Garcia; Jurjan Aman; J Wouter Jukema; Hans M G Princen
Journal:  Front Cardiovasc Med       Date:  2018-06-12

8.  The APOE3-Leiden Heterozygous Glucokinase Knockout Mouse as Novel Translational Disease Model for Type 2 Diabetes, Dyslipidemia, and Diabetic Atherosclerosis.

Authors:  Marianne G Pouwer; Suvi E Heinonen; Margareta Behrendt; Anne-Christine Andréasson; Arianne van Koppen; Aswin L Menke; Elsbet J Pieterman; Anita M van den Hoek; J Wouter Jukema; Brendan Leighton; Ann-Cathrine Jönsson-Rylander; Hans M G Princen
Journal:  J Diabetes Res       Date:  2019-02-21       Impact factor: 4.011

9.  Hypercholesterolemia affects cardiac function, infarct size and inflammation in APOE*3-Leiden mice following myocardial ischemia-reperfusion injury.

Authors:  Niek J Pluijmert; Melina C den Haan; Vanessa L van Zuylen; Paul Steendijk; Hetty C de Boer; Anton J van Zonneveld; Willem E Fibbe; Martin J Schalij; Paul H A Quax; Douwe E Atsma
Journal:  PLoS One       Date:  2019-06-14       Impact factor: 3.240

10.  Transgenic expression of dominant-active IDOL in liver causes diet-induced hypercholesterolemia and atherosclerosis in mice.

Authors:  Anna C Calkin; Stephen D Lee; Jason Kim; Caroline M W Van Stijn; Xiao-Hui Wu; Aldons J Lusis; Cynthia Hong; Rajendra I Tangirala; Peter Tontonoz
Journal:  Circ Res       Date:  2014-06-16       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.